Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

ConferenceLB2501Positive

AI Analysis

Summary

Legend Biotech announced a late-breaking oral presentation at EHA 2026 featuring initial Phase 1 in vivo CAR-T data for LB2501 in non-Hodgkin lymphoma, a positive development for the early-stage program.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Late-breaking oral presentation of Phase 1 in vivo CAR-T data

Importance:5/10

Sentiment:

0.60

CAR-TOncologyEHA 2026Non-Hodgkin LymphomaEarly-stage data

Related Companies

$LEGN

Read the original article

Published by yahoo_finance on June 2, 2026 1:30 PM

Read Original